id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-329853-kf3kh26y	Trimarchi, Hernán	Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome	2020-09-27		.txt	text/plain	1097	64	39	Complement activation is thought to contribute to endothelial injury and there are at least seven ongoing clinical trials testing six different anti-complement strategies for coronavirus disease 2019 (COVID-19), including eculizumab. We herein report on a kidney transplant patient with aHUS on chronic eculizumab therapy that developed severe COVID-19 despite eculizumab administration early in the course of the disease. Although eculizumab was unable to prevent the development of severe endothelial cell injury, as assessed by increasing D-dimer levels from 292 to 10 586 ng/mL, the patient eventually recovered following dexamethasone and convalescent plasma administration. To our knowledge, this is the first report of a kidney transplant recipient with aHUS on eculizumab therapy who developed SARS-CoV-2 infection. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases	./cache/cord-329853-kf3kh26y.txt	./txt/cord-329853-kf3kh26y.txt